TRCT
IMVT icon

Tower Research Capital (TRC)’s Immunovant IMVT Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Sell
3,672
-11,233
-75% -$342K ﹤0.01% 1942
2026
Q1 		$370K Buy
14,905
+11,353
+320% +$294K 0.01% 1142
2025
Q4 		$90.3K Sell
3,552
-2,964
-45% -$66.1K ﹤0.01% 2007
2025
Q3 		$105K Buy
6,516
+376
+6% +$6.09K ﹤0.01% 1949
2025
Q2 		$98.2K Buy
6,140
+4,273
+229% +$64.6K ﹤0.01% 2391
2025
Q1 		$31.9K Sell
1,867
-14,375
-89% -$301K ﹤0.01% 2565
2024
Q4 		$402K Buy
16,242
+15,226
+1,499% +$432K 0.01% 1216
2024
Q3 		$29K Sell
1,016
-13,126
-93% -$387K ﹤0.01% 3021
2024
Q2 		$373K Buy
14,142
+13,630
+2,662% +$388K 0.01% 1584
2024
Q1 		$16.5K Sell
512
-6,863
-93% -$250K ﹤0.01% 3172
2023
Q4 		$311K Sell
7,375
-2,253
-23% -$82.9K ﹤0.01% 1751
2023
Q3 		$370K Buy
9,628
+7,852
+442% +$177K 0.01% 1052
2023
Q2 		$33.7K Sell
1,776
-19,025
-91% -$355K ﹤0.01% 2918
2023
Q1 		$322K Buy
20,801
+17,554
+541% +$305K 0.01% 1097
2022
Q4 		$58K Sell
3,247
-8,436
-72% -$106K ﹤0.01% 2238
2022
Q3 		$65K Buy
11,683
+5,923
+103% +$29K ﹤0.01% 2923
2022
Q2 		$22K Sell
5,760
-4,670
-45% -$20.2K ﹤0.01% 3694
2022
Q1 		$57K Buy
10,430
+2,492
+31% +$15.5K ﹤0.01% 2626
2021
Q4 		$67K Sell
7,938
-2,349
-23% -$19.4K ﹤0.01% 2527
2021
Q3 		$89K Buy
10,287
+6,200
+152% +$55.9K ﹤0.01% 2499
2021
Q2 		$43K Sell
4,087
-1,659
-29% -$23.2K ﹤0.01% 3145
2021
Q1 		$92K Buy
5,746
+3,296
+135% +$86.9K ﹤0.01% 2649
2020
Q4 		$113K Sell
2,450
-1,496
-38% -$69.2K ﹤0.01% 2226
2020
Q3 		$139K Buy
3,946
+2,891
+274% +$87K ﹤0.01% 2887
2020
Q2 		$26K Buy
+1,055
New +$22.6K ﹤0.01% 3536

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s IMVT Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Immunovant (IMVT) stake by 75% in Q2 2026, selling an estimated $342K and leaving 3,672 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Tower Research Capital (TRC) first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. The position peaked at $402K in Q4 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Tower Research Capital (TRC) held 3,672 shares of Immunovant worth $141K as of Q2 2026.
  • Tower Research Capital (TRC) sold 11,233 Immunovant shares in Q2 2026, an estimated $342K.
  • Immunovant made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1942 holding.
  • Tower Research Capital (TRC) first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Immunovant position peaked at $402K in Q4 2024.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.